CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation.
about
Nicotine withdrawal.Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation.Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning.Genetic influence of dopamine receptor, dopamine transporter, and nicotine metabolism on smoking cessation and nicotine dependence in a Japanese population.Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatmentN-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth cohort.CYP2A6 Polymorphisms May Strengthen Individualized Treatment for Nicotine Dependence.Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.Biomarkers to optimize the treatment of nicotine dependence.Withdrawal: Expanding a Key Addiction Construct.Genetics and smoking cessation improving outcomes in smokers at riskOverview of the pharmacogenomics of cigarette smoking.Polygenic risk and the developmental progression to heavy, persistent smoking and nicotine dependence: evidence from a 4-decade longitudinal study.Variants in nicotinic receptors and risk for nicotine dependence.Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokersNeuroimaging, genetics and the treatment of nicotine addictionCharacteristics and health consequences of intermittent smoking: long-term follow-up among Finnish adult twinsNicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymesPharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).Pharmacogenetics of chronic obstructive pulmonary disease.To quit or not: Vulnerability of women to smoking tobacco.Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.Cytochrome P450 2A isoenzymes in freshly prepared blood lymphocytes isolated from rats and validation as a biomarker for clinical studies in humans.Variation in CYP2A6 Activity and Personalized Medicine.Preparing the Way: Exploiting Genomic Medicine to Stop Smoking.Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea.Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?
P2860
Q30404700-F66B7075-FBC7-4441-BE8D-CF9A2E7BB141Q30435362-07973E54-0948-4064-85E4-87CBB9919403Q30448530-E1D9C681-2464-4994-A050-E9398BB4FBFAQ35016329-A8DA772A-AB76-48F6-ADC7-3242B6B261D0Q35059965-761263BA-D1E5-42E6-BD64-630CD2B77DA1Q35126163-88ED2E8C-13AC-4761-AC59-8C980C92F339Q35594492-64235095-418F-4C0B-840D-07FFB57B901CQ35751986-2EC9C3AF-C9BB-4EFD-8182-6E3787BE89CEQ35773685-4D5E8AF1-C646-41F4-A4F1-D3523CC4B09AQ36303879-68D59D00-8A10-4EBD-90F9-9AEA9D512DF8Q36319935-00EBD87E-8533-4695-B2F9-3FA2355BA92DQ36708951-7D8416A0-A52A-44B8-BE4B-550449C14707Q36815235-39BB9908-236D-467F-8B4A-7449EC72888FQ36952598-20B8824A-9A3A-40A9-AE58-EFED181C96FCQ36974499-3A9E806E-BCF1-4BAF-B020-E4503F770171Q37010016-460054A1-12C5-4883-9A30-C505D87219A9Q37136061-04E45570-4B63-4C4E-94C9-5A36FF3E0525Q37169244-120DA56F-F1AE-4022-8F8F-5C8363219F97Q37395740-2EEE9DD5-D768-492B-AD4D-130311DF0D65Q37625427-A02A45CD-4F1A-4836-B8FA-E92CBA32F48AQ38121970-5F90FA5E-E5A0-4A15-933B-C38237218DC4Q38669817-04E049A5-E569-4512-9005-025C6FF0B521Q38683483-E4262C17-BD2F-4F2F-B891-01821B62A980Q42716206-4A0D272A-EEB2-42E2-B203-8A09957FB8A3Q47163198-B4243B18-E02C-4387-AF7B-000FB54B71FDQ47200916-950FF138-22C8-4AB6-A026-A4AFD1A82967Q47735887-CC3F7739-E1B5-47A9-98A3-852D1E8EA6DFQ47742671-3789DA38-5F6F-4B97-A5C6-5D599BCF2EC4
P2860
CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
CYP2A6 polymorphisms are assoc ...... symptoms in smoking cessation.
@en
CYP2A6 polymorphisms are assoc ...... symptoms in smoking cessation.
@nl
type
label
CYP2A6 polymorphisms are assoc ...... symptoms in smoking cessation.
@en
CYP2A6 polymorphisms are assoc ...... symptoms in smoking cessation.
@nl
prefLabel
CYP2A6 polymorphisms are assoc ...... symptoms in smoking cessation.
@en
CYP2A6 polymorphisms are assoc ...... symptoms in smoking cessation.
@nl
P2093
P2860
P356
P1476
CYP2A6 polymorphisms are assoc ...... symptoms in smoking cessation.
@en
P2093
C Nakajima-Taniguchi
K Kawashima
M Funamoto
P2860
P2888
P304
P356
10.1038/SJ.TPJ.6500348
P577
2006-03-01T00:00:00Z